Table 4.
Results of multivariate regression analysis including Mammostrat® risk score
| ER-positive, node-negative, tamoxifen only a | ER-positive, tamoxifen only a | All ER-positive cases | All Eligible cases | |
|---|---|---|---|---|
| Relapse-free survival | ||||
| Nodal status | * | 5.4 × 10-8 | 0.0001 | 2.8 × 10-9 |
| Grade | NS | 0.046 | NS | NS |
| Size | NS | 0.010 | 7.0 × 10-5 | 0.0007 |
| Multifocality | 0.037 | 0.001 | 0.0004 | 0.0004 |
| Menopausal status | 0.031 | 0.013 | 0.048 | NS |
| Age | NS | NS | NS | NS |
| HER2 | 0.012 | 0.0005 | 0.003 | 0.001 |
| PgR | NS | NS | 0.079 | NS |
| ER | * | * | * | NS |
| Mammostrat® | 0.076 | 0.064 | 0.025 | 0.0007 |
| Distant recurrence-free survival | ||||
| Nodal status | * | 3.7 × 10-7 | 5.1 × 10-5 | 4.6 × 10-9 |
| Grade | NS | 0.067 | NS | NS |
| Size | 0.091 | 0.0004 | 0.002 | |
| Multifocality | NS | NS | 0.030 | 0.082 |
| Menopausal status | NS | NS | NS | NS |
| Age | NS | NS | NS | NS |
| HER2 | 0.092 | 0.01 | 0.021 | 0.024 |
| PgR | NS | NS | NS | NS |
| ER | * | * | * | NS |
| Mammostrat® | 0.059 | 0.012 | 0.005 | 6.6x10-5 |
| Overall survival | ||||
| Nodal status | * | 2.5 × 10-6 | 6.9 × 10-5 | 9.1 × 10-9 |
| Grade | NS | 0.074 | 0.036 | 0.088 |
| Size | 0.018 | 0.00021 | 0.011 | |
| Multifocality | NS | NS | 0.061 | NS |
| Menopausal status | NS | NS | NS | NS |
| Age | NS | 0.080 | 0.037 | 0.017 |
| HER2 | NS | NS | NS | NS |
| PgR | NS | 0.059 | 0.085 | NS |
| ER | * | * | * | 0.001 |
| Mammostrat® | NS | NS | 0.0023 | 0.005 |
Data represent P value for significance of individual factors in multivariate analyses. ER, estrogen receptor; NS, not significant. Nodal status, node-positive versus node-negative; grade, grade 1, grade 2 or grade 3; size, < 2 cm vs. ≥ 2 cm; multifocality, presence or absence of multifocal disease; menopausal status, premenopausal versus postmenopausal; age, < 55 years versus ≥ 55 years; HER2, HER2-positive versus HER2-negative; PgR (progesterone receptor) and ER, hormone receptor-positive versus hormone receptor-negative; Mammostrat®, risk category low, medium or high. aTamoxifen only, patients treated with adjuvant tamoxifen without adjuvant chemotherapy. * = not relevant as no stratification, e.g. nodal status in node negative patients.